On September 7, 2021 Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference (Press release, Revolution Medicines, SEP 7, 2021, View Source [SID1234587296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

H.C. Wainwright 23rd Annual Global Investment Conference
Conference Dates: September 13-15, 2021
Presentation Timing: 7:00 a.m. Eastern on Monday, September 13, 2021
Format: Virtual conference; webcast available
To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines’ website at View Source Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the conference.

On September 7, 2021 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, reported that management will participate in three upcoming investor conferences (Press release, IGM Biosciences, SEP 7, 2021, View Source [SID1234587313]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9
Fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13 at 2:45 p.m. EDT
Fireside chat at Baird’s 2021 Global Consumer, Technology & Services Conference on Tuesday, September 14 at 2:35 p.m. EDT
A live webcast of the Morgan Stanley fireside chat will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

On September 7, 2021 BeyondSpring Inc. ("BeyondSpring") (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, reported that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time (Press release, BeyondSpring Pharmaceuticals, SEP 7, 2021, View Source;utm_medium=rss&utm_campaign=beyondspring-to-host-second-quarter-financial-results-and-corporate-update-conference-call-on-september-10-2021 [SID1234587329]). Details for the conference call are below:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Friday, September 10 @ 8:00 AM Eastern Time
Domestic: 877-451-6152
International: 201-389-0879
Conference ID: 13722968
Webcast: View Source
An archived replay of the webcast will be available for 90 days on BeyondSpring’s website at www.beyondspringpharma.com under "Events & Presentations" in the Investors section.

On September 7, 2021 Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that the Company will present at three upcoming virtual investor conferences in September (Press release, Marker Therapeutics, SEP 7, 2021, View Source [SID1234587345]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details

H.C. Wainwright Annual Global Investment Conference
Company Presenter: Anthony H. Kim, Chief Financial Officer
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m. ET

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Company Presenter: Mythili Koneru, M.D., Ph.D., Chief Medical Officer
Date: Wednesday, September 22, 2021
Time: 9:05 a.m. ET

Cantor Fitzgerald Global Healthcare Conference
Fireside Chat
Date: Monday, September 27, 2021
Time: 10:40 a.m. ET

Live webcasts of the presentations will be accessible from the Investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.

On September 7, 2021 Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, reported that Jonathan Drachman, M.D., Chief Executive Officer, will present a corporate overview during the H.C. Wainwright 23RD Annual Global Life Sciences Conference taking place September 13-15, 2021 (Press release, Neoleukin Therapeutics, SEP 7, 2021, View Source [SID1234587361]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded presentation will be available for on-demand access beginning at 7:00 am ET on Monday, September 13, 2021 from the investors section of the Neoleukin website at View Source An archived replay will also be available on the company website for at least 30 days following the event.